Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 270213, 8 pages
http://dx.doi.org/10.1155/2014/270213
Research Article

Effects of Recombinant Human Thyrotropin Administration on 24-Hour Arterial Pressure in Female Undergoing Evaluation for Differentiated Thyroid Cancer

1Endocrine Unit, Department Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80 Vass Sofias Avenue, 11528 Athens, Greece
2Endocrine Unit, Evgenidion Hospital, Athens University School of Medicine, 80 Vass Sofias Avenue, Athens, Greece
3Hypertension Unit, Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80 Vass Sofias Avenue, 11528 Athens, Greece
4Vascular Laboratory, Department of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80 Vass Sofias Avenue, 11528 Athens, Greece

Received 17 February 2014; Revised 28 July 2014; Accepted 29 July 2014; Published 18 August 2014

Academic Editor: Mario Maggi

Copyright © 2014 Gianna Rentziou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Kotsis, M. Alevizaki, S. Stabouli et al., “Hypertension and hypothyroidism: results from an ambulatory blood pressure monitoring study,” Journal of Hypertension, vol. 25, no. 5, pp. 993–999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Lekakis, C. Papamichael, M. Alevizaki et al., “Flow-mediated, endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values,” Thyroid, vol. 7, no. 3, pp. 411–414, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Biondi and I. Klein, “Hypothyroidism as a risk factor for cardiovascular disease,” Endocrine, vol. 24, no. 1, pp. 1–13, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. O. Åsvold, T. Bjøro, T. I. L. Nilsen, and L. J. Vatten, “Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based study,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 3, pp. 841–845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Chen, Q. Xi, H. Zhang et al., “Investigation of thyroid function and blood pressure in school-aged subjects without overt thyroid disease,” Endocrine, vol. 41, no. 1, pp. 122–129, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Davies, R. Marians, and R. Latif, “The TSH receptor reveals itself,” The Journal of Clinical Investigation, vol. 110, no. 2, pp. 161–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Murakami, Y. Kamiya, T. Morimura et al., “Thyrotropin receptors in brown adipose tissue: thyrotropin stimulates type II iodothyronine deiodinase and uncoupling protein-1 in brown adipocytes,” Endocrinology, vol. 142, no. 3, pp. 1195–1201, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Bell, A. Gagnon, L. Grunder, S. J. Parikh, T. J. Smith, and A. Sorisky, “Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts,” American Journal of Physiology: Cell Physiology, vol. 279, no. 2, pp. C335–C340, 2000. View at Google Scholar · View at Scopus
  9. D. Donnini, F. S. Ambesi-Impiombato, and F. Curcio, “Thyrotropin stimulates production of procoagulant and vasodilatative factors in human aortic endothelial cells,” Thyroid, vol. 13, no. 6, pp. 517–521, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. B. R. Haugen, D. S. Cooper, C. H. Emerson et al., “Expanding indications for recombinant human TSH in thyroid cancer,” Thyroid, vol. 18, no. 7, pp. 687–694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Martini, L. Gennari, V. de Paola et al., “The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels,” Thyroid, vol. 18, no. 4, pp. 455–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Sorvillo, G. Mazziotti, A. Carbone et al., “Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 10, pp. 4818–4822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Dardano, L. Ghiadoni, Y. Plantinga et al., “Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4175–4178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Napoli, B. Biondi, V. Guardasole et al., “Enhancement of vascular endothelial function by recombinant human thyrotropin,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 5, pp. 1959–1963, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Biondi, E. A. Palmieri, L. Pagano et al., “Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 211–214, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Murialdo, M. Casu, C. Cappi et al., “Effects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on I-thyroxine-suppressive therapy for differentiated thyroid carcinoma,” Hormone Research, vol. 64, no. 2, pp. 100–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Sader and D. S. Celermajer, “Endothelial function, vascular reactivity and gender differences in the cardiovascular system,” Cardiovascular Research, vol. 53, no. 3, pp. 597–604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Saltiki and M. Alevizaki, “Coronary heart disease in postmenopausal women; the role of endogenous estrogens and their receptors.,” Hormones, vol. 6, no. 1, pp. 9–24, 2007. View at Google Scholar · View at Scopus
  19. M. Hamer and E. Stamatakis, “Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 7, pp. 2482–2488, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Jacobs, J. W. Lenders, J. A. Kapma, P. Smits, and T. Thien, “Effect of chronic smoking on endothelium-dependent vascular relaxation in humans,” Clinical Science, vol. 85, no. 1, pp. 51–55, 1993. View at Google Scholar · View at Scopus
  21. H. Moreno Jr., S. Chalon, A. Urae et al., “Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation,” American Journal of Physiology, vol. 275, no. 3, pp. H1040–H1045, 1998. View at Google Scholar · View at Scopus
  22. . Mancia G, G. De Backer, and A. Dominiczak, “2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” Journal of Hypertension, vol. 25, no. 6, pp. 1105–1187, 2007. View at Publisher · View at Google Scholar
  23. American Diabetes Association, “Executive summary: standards of medical care in diabetes—2012,” Diabetes Care, vol. 35, supplement 1, pp. S4–S10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. L. Catapano, Z. Reiner, G. De Backer et al., “European Association for Cardiovascular Prevention & Rehabilitation, ESC/EAS Guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS),” European Heart Journal, vol. 32, no. 14, pp. 1769–1818, 2011. View at Google Scholar
  25. World Health Organization (WHO), “Obesity and overweight,” Fact sheet No. 311, http://www.who.int/mediacentre/factsheets/fs311/en.
  26. C. H. Chen, E. Nevo, B. Fetics et al., “Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function,” Circulation, vol. 95, no. 7, pp. 1827–1836, 1997. View at Publisher · View at Google Scholar
  27. B. Williams, P. S. Lacy, S. M. Thom et al., “Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study,” Circulation, vol. 113, no. 9, pp. 1213–1225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. L. Pauca, M. F. O'Rourke, and N. D. Kon, “Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform,” Hypertension, vol. 38, no. 4, pp. 932–937, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Sega, G. Corrao, M. Bombelli et al., “Blood pressure variability and organ damage in a general population: results from the PAMELA study,” Hypertension, vol. 39, no. 2, part 2, pp. 710–714, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Kikuya, A. Hozawa, T. Ohokubo et al., “Prognostic significance of blood pressure and heart rate variabilities: the Ohasama Study,” Hypertension, vol. 36, no. 5, pp. 901–906, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Roman, R. B. Devereux, J. R. Kizer et al., “Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the strong heart study,” Hypertension, vol. 50, no. 1, pp. 197–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Safar, “Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors,” Current Opinion in Nephrology and Hypertension, vol. 10, no. 2, pp. 257–261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Drvota, A. Janson, C. Norman et al., “Evidence for the presence of functional thyrotropin receptor in cardiac muscle,” Biochemical and Biophysical Research Communications, vol. 211, no. 2, pp. 426–431, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. D. F. Sellitti, R. Hill, S. Q. Doi et al., “Differential expression of thyrotropin receptor mRNA in the porcine heart,” Thyroid, vol. 7, no. 4, pp. 641–646, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. D. F. Sellitti, D. Dennison, T. Akamizu, S. Q. Doi, L. D. Kohn, and H. Koshiyama, “Thyrotropin regulation of cyclic adenosine monophosphate production inhuman coronary artery smooth muscle cells,” Thyroid, vol. 10, no. 3, pp. 219–225, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Giusti, S. Valenti, B. Guazzini et al., “Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant,” Journal of Endocrinological Investigation, vol. 26, no. 12, pp. 1192–1197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Saltiki, P. Voidonikola, K. Stamatelopoulos et al., “Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: a cross-sectional study,” Thyroid Research, vol. 1, no. 1, pp. 1756–1766, 2008. View at Google Scholar
  38. T. Ittermann, D. Tiller, C. Meisinger et al., “High serum thyrotropin levels are associated with current but not with incident hypertension,” Thyroid, vol. 23, no. 8, pp. 955–963, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. A. P. Weetman, R. Bright-Thomas, and M. Freeman, “Regulation of interleukin-6 release by human thyrocytes,” The Journal of Endocrinology, vol. 127, no. 2, pp. 357–361, 1990. View at Publisher · View at Google Scholar · View at Scopus